Information Provided By:
Fly News Breaks for September 23, 2015
HRTX, PCRX
Sep 23, 2015 | 08:45 EDT
Canaccord analyst Corey Davis acknowledged that Phase 2 data on Heron Therapeutics' (HRTX)HTX-011, a potential competitor to Pacira's (PCRX) Exparel, "appear impressive" on the surface, but notes that there are "challenges still to come" that "many have missed in the initial euphoria." Davis said that the 200mg dose of HTX-011 didn't work, adding that the 400mg dose that did work is a "very high dose of bupivacaine," while noting that the bunionectomy dose in Exparel's label is 106mg. If HTX-011 comes in a non-dilutable 5 ml volume, as the firm believes, it could be a problem commercially for the drug since volumes differ greatly based on the type of procedure, the analyst also contends. Davis has a $76 price target and Buy rating on Pacira.
News For PCRX;HRTX From the Last 2 Days
There are no results for your query PCRX;HRTX